PMID- 29755954 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220317 IS - 2234-943X (Print) IS - 2234-943X (Electronic) IS - 2234-943X (Linking) VI - 8 DP - 2018 TI - Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma. PG - 127 LID - 10.3389/fonc.2018.00127 [doi] LID - 127 AB - BACKGROUND AND OBJECTIVE: Diffuse intrinsic pontine glioma (DIPG) is a lethal brainstem tumor in children. Dendritic cells (DCs) have T-cell stimulatory capacity and, therefore, potential antitumor activity for disease control. DCs vaccines have been shown to reactivate tumor-specific T cells in both clinical and preclinical settings. We designed a phase Ib immunotherapy (IT) clinical trial with the use of autologous dendritic cells (ADCs) pulsed with an allogeneic tumors cell-lines lysate in patients with newly diagnosed DIPG after irradiation (radiation therapy). METHODS: Nine patients with newly diagnosed DIPG met enrollment criteria. Autologous dendritic cell vaccines (ADCV) were prepared from monocytes obtained by leukapheresis. Five ADCV doses were administered intradermally during induction phase. In the absence of tumor progression, patients received three boosts of tumor lysate every 3 months during the maintenance phase. RESULTS: Vaccine fabrication was feasible in all patients included in the study. Non-specific KLH (9/9 patients) and specific (8/9 patients) antitumor response was identified by immunologic studies in peripheral blood mononuclear cells (PBMC). Immunological responses were also confirmed in the T lymphocytes isolated from the cerebrospinal fluid (CSF) of two patients. Vaccine administration resulted safe in all patients treated with this schema. CONCLUSION: These preliminary results demonstrate that ADCV preparation is feasible, safe, and generate a DIPG-specific immune response detected in PBMC and CSF. This strategy shows a promising backbone for future schemas of combination IT. FAU - Benitez-Ribas, Daniel AU - Benitez-Ribas D AD - Department of Immunology, Hospital Clinic, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain. FAU - Cabezon, Raquel AU - Cabezon R AD - Department of Immunology, Hospital Clinic, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain. FAU - Florez-Grau, Georgina AU - Florez-Grau G AD - Department of Immunology, Hospital Clinic, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain. FAU - Molero, Mari Carmen AU - Molero MC AD - Department of Clinical Trials, Hospital Sant Joan de Deu, Barcelona, Spain. FAU - Puerta, Patricia AU - Puerta P AD - Department of Neurosurgery, Hospital Sant Joan de Deu, Barcelona, Spain. FAU - Guillen, Antonio AU - Guillen A AD - Department of Neurosurgery, Hospital Sant Joan de Deu, Barcelona, Spain. FAU - Paco, Sonia AU - Paco S AD - Laboratory of Developmental Cancer, Institut de Recerca Sant Joan de Deu, Barcelona, Spain. AD - Department of Oncology and Hematology, Hospital Sant Joan de Deu, Barcelona, Spain. FAU - Carcaboso, Angel M AU - Carcaboso AM AD - Laboratory of Developmental Cancer, Institut de Recerca Sant Joan de Deu, Barcelona, Spain. AD - Department of Oncology and Hematology, Hospital Sant Joan de Deu, Barcelona, Spain. FAU - Santa-Maria Lopez, Vicente AU - Santa-Maria Lopez V AD - Department of Oncology and Hematology, Hospital Sant Joan de Deu, Barcelona, Spain. AD - Department of Neuro-Oncology, Hospital Sant Joan de Deu, Barcelona, Spain. FAU - Cruz, Ofelia AU - Cruz O AD - Department of Oncology and Hematology, Hospital Sant Joan de Deu, Barcelona, Spain. AD - Department of Neuro-Oncology, Hospital Sant Joan de Deu, Barcelona, Spain. FAU - de Torres, Carmen AU - de Torres C AD - Laboratory of Developmental Cancer, Institut de Recerca Sant Joan de Deu, Barcelona, Spain. AD - Department of Oncology and Hematology, Hospital Sant Joan de Deu, Barcelona, Spain. FAU - Salvador, Noelia AU - Salvador N AD - Laboratory of Developmental Cancer, Institut de Recerca Sant Joan de Deu, Barcelona, Spain. AD - Department of Oncology and Hematology, Hospital Sant Joan de Deu, Barcelona, Spain. FAU - Juan, Manel AU - Juan M AD - Department of Immunology, Hospital Clinic, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), University of Barcelona, Barcelona, Spain. AD - Department of Immunotherapy, Hospital Sant Joan de Deu, Barcelona, Spain. FAU - Mora, Jaume AU - Mora J AD - Laboratory of Developmental Cancer, Institut de Recerca Sant Joan de Deu, Barcelona, Spain. AD - Department of Oncology and Hematology, Hospital Sant Joan de Deu, Barcelona, Spain. FAU - La Madrid, Andres Morales AU - La Madrid AM AD - Laboratory of Developmental Cancer, Institut de Recerca Sant Joan de Deu, Barcelona, Spain. AD - Department of Oncology and Hematology, Hospital Sant Joan de Deu, Barcelona, Spain. AD - Department of Neuro-Oncology, Hospital Sant Joan de Deu, Barcelona, Spain. LA - eng PT - Journal Article DEP - 20180426 PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 EIN - Front Oncol. 2018 Jun 05;8:201. PMID: 29897054 PMC - PMC5932163 OTO - NOTNLM OT - cell OT - dendritic OT - diffuse intrinsic pontine glioma OT - immunotherapy OT - vaccination EDAT- 2018/05/15 06:00 MHDA- 2018/05/15 06:01 PMCR- 2018/01/01 CRDT- 2018/05/15 06:00 PHST- 2018/01/16 00:00 [received] PHST- 2018/04/06 00:00 [accepted] PHST- 2018/05/15 06:00 [entrez] PHST- 2018/05/15 06:00 [pubmed] PHST- 2018/05/15 06:01 [medline] PHST- 2018/01/01 00:00 [pmc-release] AID - 10.3389/fonc.2018.00127 [doi] PST - epublish SO - Front Oncol. 2018 Apr 26;8:127. doi: 10.3389/fonc.2018.00127. eCollection 2018.